Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

NCT ID: NCT00723983

Last Updated: 2016-02-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 23 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-11-30
• Study Completion Date: 2009-09-30

Brief Summary

To compare the pharmacokinetics of NP101 with a currently approved oral formulation of Imitrex® (50 mg) in migraine subjects both during an acute migraine attack and during a non-migraine period.

Conditions

Migraine Disorders

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Period 1

Subject dosed with oral sumatriptan succinate during an acute migraine attack.

Group Type: ACTIVE_COMPARATOR

Sumatriptan succinate

Intervention Type: DRUG

Sumatriptan succinate 50 mg taken orally

Period 2

Subject dosed with oral sumatriptan during a non-migraine period.

Group Type: ACTIVE_COMPARATOR

Sumatriptan succinate

Intervention Type: DRUG

Sumatriptan succinate 50 mg taken orally

Period 3 and Period 6

Subject dosed with NP101 during an acute migraine attack.

Group Type: EXPERIMENTAL

NP101 Study Patch

Intervention Type: DRUG

NP101 study patch 4 hour application

Period 4 and Period 5

Subject dosed with NP101 study patch during a non-migraine period.

Group Type: EXPERIMENTAL

NP101 Study Patch

Intervention Type: DRUG

NP101 study patch 4 hour application

Interventions

Sumatriptan succinate

Sumatriptan succinate 50 mg taken orally

Intervention Type: DRUG

NP101 Study Patch

NP101 study patch 4 hour application

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Adult male and female subjects, between the ages of 18 to 65 years.
• Subjects with a diagnosis of migraine headache, with or without aura, as defined in the ICHD-II, and the diagnosis was made before the age of 50.
• The majority of a subject's headaches during a migraine attack are moderate to severe in intensity.
• Subject has history of regularly occuring migraines, accompanied by nausea or vomiting.
• Subject has at least one year history of migraine based upon subject testimony.
• Subject will be judged to be in good health, based upon the results of a medical history, physical examination, vital signs, ECG and laboratory profile.
• Subjects must voluntarily sign and date and Informed Consent agreement approved by an IRB.
• Subject must have a negative drug screen and re-screen.
• Female subjects of childbearing potential must have a negative pregnancy test at Screening and Re-Screening.
• Subject has two acceptable patch application sites.

Exclusion Criteria

• Subject has or plans to start stop, or change treatment (including dose change) of any medication within one month prior to the subject screening date and through the end of study.
• Subject has less than 2 migraines per month or subject has more than 15 headache days/month for any of the 3 months prior ot screening.
• Subject who has suspected or confirmed cardiovascular disease that contraindicates study participation.
• Subject has history of epilepsy or conditions associated with lower seizure threshold.
• Subject with Raynaud's disease.
• Subject with hemiplegic or basilar migraine.
• Subject with a current diagnosis of major depressive disorder.
• Subject who has taken non-triptan serotonergic drugs including SSRI's, SNRI, TCAs or MAOI's or preparations containing St. John's Wort within month prior to screening and/or is planning to start any of these medications during the study and through the End of Study Visit.
• Subject is unwilling to discontinue use of PD5 inhibitors (eg. Viagra, Levitra, Cialis) from screening through End of Study Visit.
• Subject with a history of significant allergy or hypersensitivity to any component of the NP101 study patch.
• Subject who has any generalized skin irritation or disease including eczema, psoriasis, melanoma, acne or contact dermatitis.
• Subject has a positive test result for hepatitis B, hepatitis C or is known to be HIV positive.
• Subjects with moderate or severe hepatic dysfunction defined as SGOT/AST or SGPT/ALT ≥ 2 times the upper limit of normal range, or alkaline phosphatase or total bilirubin ≥ 1.5 times the upper limit of normal range or if in the opinion of the investigator, the subject's history, physical examination or other laboratory tests suggest hepatic dysfunction.
• Female subjects who are pregnant, breast feeding, or if not of childbearing potential, is not using or is unwilling to use an effective form of contraception during the study and for a period of 30 days following final dosing.
• Subjects with a known history of tolerability issues with sumatriptan.
• Subject who is considered by the investigator or NuPathe to be an unsuitable candidate for this study.
• Subject has a history (within 1 year) or current evidence of drug or alcohol abuse or dependence.
• Subject has participated in a clinical study within 30 days of Screening or is planning to participate in another clinical study.
• Subject has clinically significant abnormal labs, vital signs or ECG
• Subject is electrically sensitive or who has an implantable electronic device.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

NuPathe Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kerri L Wilks, MD, CPI

Role: PRINCIPAL_INVESTIGATOR

MD Clinic

Locations

MD Clinic

Hallandale, Florida, United States

Countries

United States

Other Identifiers

PROT-15-NP101-011

Identifier Type: -

Identifier Source: org_study_id